Crinetics Pharmaceuticals Inc
NASDAQ:CRNX

Watchlist Manager
Crinetics Pharmaceuticals Inc Logo
Crinetics Pharmaceuticals Inc
NASDAQ:CRNX
Watchlist
Price: 60.69 USD 1.47% Market Closed
Market Cap: 5.4B USD
Have any thoughts about
Crinetics Pharmaceuticals Inc?
Write Note

Balance Sheet

Balance Sheet Decomposition
Crinetics Pharmaceuticals Inc

Current Assets 874.8m
Cash & Short-Term Investments 863m
Receivables 4.8m
Other Current Assets 7m
Non-Current Assets 60.8m
PP&E 57.3m
Other Non-Current Assets 3.5m
Current Liabilities 54.4m
Accounts Payable 8.9m
Accrued Liabilities 42.9m
Other Current Liabilities 2.6m
Non-Current Liabilities 50.4m
Other Non-Current Liabilities 50.4m

Balance Sheet
Crinetics Pharmaceuticals Inc

Rotate your device to view
Balance Sheet
Currency: USD
Dec-2016 Dec-2017 Dec-2018 Dec-2019 Dec-2020 Dec-2021 Dec-2022 Dec-2023
Assets
Cash & Cash Equivalents
12
14
45
40
93
201
33
55
Cash Equivalents
12
14
45
40
93
201
33
55
Short-Term Investments
0
0
119
78
78
133
302
504
Total Receivables
0
1
2
1
2
2
2
9
Other Current Assets
0
0
1
4
5
10
9
7
Total Current Assets
12
15
167
123
178
345
345
574
PP&E Net
0
0
4
7
5
5
5
57
PP&E Gross
0
0
4
7
5
5
5
57
Accumulated Depreciation
0
0
1
2
3
4
4
5
Long-Term Investments
0
0
0
0
0
1
0
0
Other Long-Term Assets
0
0
1
1
1
1
2
3
Total Assets
13
N/A
16
+24%
171
+999%
130
-24%
183
+41%
351
+91%
352
+0%
635
+80%
Liabilities
Accounts Payable
0
0
2
5
6
9
7
7
Accrued Liabilities
1
1
7
4
5
8
19
35
Short-Term Debt
0
0
0
0
0
0
0
0
Current Portion of Long-Term Debt
0
0
0
0
0
0
0
0
Other Current Liabilities
0
0
0
0
0
0
2
2
Total Current Liabilities
1
1
8
8
11
16
28
44
Long-Term Debt
0
0
0
0
0
0
0
0
Other Liabilities
0
0
3
5
4
3
8
52
Total Liabilities
1
N/A
1
-18%
11
+1 144%
13
+18%
15
+10%
19
+32%
36
+87%
96
+169%
Equity
Common Stock
18
30
0
211
337
608
759
1 192
Retained Earnings
7
16
43
94
168
275
439
654
Additional Paid In Capital
1
1
204
0
0
0
0
0
Other Equity
0
0
0
0
0
0
4
1
Total Equity
12
N/A
15
+28%
160
+990%
117
-27%
169
+44%
332
+97%
316
-5%
539
+70%
Total Liabilities & Equity
13
N/A
16
+24%
171
+999%
130
-24%
183
+41%
351
+91%
352
+0%
635
+80%
Shares Outstanding
Common Shares Outstanding
22
22
24
24
33
48
54
68

See Also

Discover More